Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice

Acta Pharmacologica Sinica

Volumn 35, Issue 8, 2014, Pages 1005-1014

  Weng, Li Qing ^a   Zhang, Wen Bin ^b   Ye, Yong ^a   Yin, Pei Pei ^a   Yuan, Jie ^a   Wang, Xing Xu ^a   Kang, Le ^a   Jiang, Sha Sha ^a   You, Jie Yun ^a   Wu, Jian ^a   Gong, Hui ^a   Ge, Jun Bo ^a   Zou, Yun Zeng ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

3 methyladenine; Aliskiren; Angiotensin II; Autophagy; Cardiac hypertrophy; Cardiomyocyte; ERK1 2; LY333531; PKC; Pressure overload; Renin

Indexed keywords

3 METHYLADENINE; ALISKIREN; ANGIOTENSIN II; AUTOPHAGY PROTEIN 16; AUTOPHAGY PROTEIN 5; BECLIN 1; COLLAGEN TYPE 1; COLLAGEN TYPE 3; JANUS KINASE 1; JANUS KINASE 2; LC 3 II PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; AORTA PRESSURE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROCEDURES; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; FIBROSIS; HEART; HEART MUSCLE; MECHANICAL STRESS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AUTOPHAGY; CARDIOMEGALY; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; FUMARATES; HEART; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL;

EID: 84905648975     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.45     Document Type: Article

References (29)

1. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
3. de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008; 29: 741-7.
4. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
5. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
6. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
7. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013; 10: 125-34.
8. Siragy HM. Rationale for combining a direct renin inhibitor with other renin-angiotensin system blockers. Focus on aliskiren and combinations. Cardiovasc Drugs Ther 2011; 25: 87-97.
9. Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Kober L, et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Failure 2012; 14: 185-92.
10. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the reninangiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344: e42.
11. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012; 7: 76-85.
12. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117: 1782-93.
13. Rothermel BA, Hill JA. Autophagy in load-induced heart disease. Circ Res 2008; 103: 1363-9.
14. Steinberg SF. Cardiac actions of protein kinase C isoforms. Physiology (Bethesda) 2012; 27: 130-9.
15. Liu Q, Molkentin JD. Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol 2011; 51: 474-8.
16. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006; 114: 574-82.
17. Roman BB, Geenen DL, Leitges M, Buttrick PM. PKC-beta is not necessary for cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2001; 280: H2264-70.
18. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
19. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53- induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-8.
20. Akers WS, Cross A, Speth R, Dwoskin LP, Cassis LA. Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol 2000; 279: H2797-806.
21. Zhang WB, Du QJ, Li H, Sun AJ, Qiu ZH, Wu CN, et al. The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med 2012; 16: 2227-37.
22. Xu X, Hua Y, Nair S, Zhang Y, Ren J. Akt2 knockout preserves cardiac function in high-fat diet-induced obesity by rescuing cardiac autophagosome maturation. J Mol Cell Biol 2013; 5: 61-3.
23. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050-5.
24. Xu X, Hua Y, Nair S, Bucala R, Ren J. Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy. Hypertension 2014; 63: 490-9.
25. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y, et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A 2011; 108: 4123-8.
26. Nemchenko A, Chiong M, Turer A, Lavandero S, Hill JA. Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol 2011; 51: 584-93.
27. Simonis G, Briem SK, Schoen SP, Bock M, Marquetant R, Strasser RH. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem 2007; 305: 103-11.
28. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-54.
29. Campbell DJ, Zhang Y, Kelly DJ, Gilbert RE, McCarthy DJ, Shi W, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol 2011; 38: 623-31.